AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection

/in , /by

Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent in SOMAmer® technology used to discover new biomarkers

/in , /by

AmberGen-SomaLogic Press Release

AmberGen awarded Phase I SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions

/in /by

AmberGen receives US Patent 7,897,335 for electrophoresis-free methods of high sensitivity detection of chain truncation mutations using tagged translated nascent proteins

/in , /by

AmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnostic

/in , /by

Promega distributes AmberGen’s fluorescent tRNA based protein engineering technology

/in , /by

https://www.promega.com/products/protein-expression/protein-labeling-and-detection/fluorotect-greenlys-in-vitro-translation-labeling-system/

Link Technologies Ltd. offers AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents in Europe

/in , /by

http://www.linktech.co.uk/products/modifiers/photocleavable_modifiers